Avalyn Pharma, Inc. (AVLN)
27.15
+1.47
(+5.72%)
USD |
NASDAQ |
Jul 17, 10:25
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.204B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.152 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA. |
| URL | http://www.avalynpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Aug. 14, 2026 (est.) |
| Last Earnings Release | Jun. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA. |
| URL | http://www.avalynpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Aug. 14, 2026 (est.) |
| Last Earnings Release | Jun. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |